EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS

Geert R. D'Haens  ¹     Peter D.R. Higgins  ²     Laurent Peyrin-Biroulet  ³     Bruce E. Sands  ⁴     Scott D. Lee  ⁵     Richard Moses  ⁶     Isabel Redondo  ⁷     Rodrigo Escobar  ⁸     Nathan Morris     Taku Kobayashi  ^9    
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
² University of Michigan, Ann Arbor, United States
³ University Hospital of Nancy, Vandoeuvre-les-Nancy, France
⁴ Icahn School of Medicine at Mount Sinai, New York, United States
⁵ University of Washington Medical Center, Seattle, United States
⁶ Eli Lilly and Company, Indianapolis, United States
⁷ Eli Lilly Portugal, Lisbon, Portugal
⁸ Lilly S.A., Alcobendas, Spain
⁹ Kitasato University Kitasato Institute Hospital, Minato-ku, Japan

Topic
Endoscopy, Histopathology, IBD

Session
The new kids on the block for IBD: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)